|
市場調査レポート
商品コード
1676165
アトピー性皮膚炎治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2025年から2033年までの予測Global Atopic Dermatitis Drugs Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033 |
||||||
カスタマイズ可能
|
|||||||
| アトピー性皮膚炎治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2025年から2033年までの予測 |
|
出版日: 2025年03月01日
発行: Value Market Research
ページ情報: 英文 155 Pages
納期: 即日から翌営業日
|
- 全表示
- 概要
- 図表
- 目次
アトピー性皮膚炎治療の世界市場規模は、2024年の81億9,000万米ドルから2033年には151億3,000万米ドルに成長すると予測され、2026～2033年の予測期間中に7.06％の堅調な年間平均成長率（CAGR）を示します。
アトピー性皮膚炎治療市場は、慢性炎症性皮膚疾患であるアトピー性皮膚炎の有病率が上昇を続けていることから、大きな成長が見込まれています。アトピー性皮膚炎は、皮膚の乾燥、かゆみ、炎症を特徴とし、患者のQOLに大きな影響を与えます。アトピー性皮膚炎とその管理に対する意識の高まりが、効果的な治療オプションに対する需要を後押ししています。医療プロバイダーが患者の転帰を改善し、症状の負担を軽減しようと努める中、アトピー性皮膚炎治療市場の繁栄が期待されています。
技術の進歩は、アトピー性皮膚炎治療市場の将来を形作る上で重要な役割を果たしています。副腎皮質ステロイドや非ステロイド性抗炎症薬などの局所治療における技術革新は、再燃の管理や長期的なコントロールを強化しています。さらに、炎症に関与する特定の経路を標的とした生物学的療法の開発も盛んになっています。製薬企業が研究と臨床検査への投資を続けていることから、市場では、有効性と安全性のプロファイルを改善した新規治療の採用が増加するとみられます。
さらに、個別化医療や患者中心の治療が重視されるようになっていることも、アトピー性皮膚炎治療市場の成長軌道に影響を与えています。患者が治療計画に積極的に参加するようになるにつれ、個人のニーズや嗜好に対応した治療に対する需要が高まっています。この動向は、医療従事者、研究開発者、患者の連携を促進し、服薬アドヒアランスと満足度を高めるオーダーメイドの治療戦略を開発しています。市場が進化を続ける中、技術、個別化アプローチ、患者教育の統合が成功の重要な促進要因となると考えられます。
当社のレポートは、様々な産業や市場に関する包括的かつ実用的な洞察をクライアントに提供するために綿密に作成されています。各レポートは、市場情勢を完全に理解するために、いくつかの重要な要素を含んでいます。
市場概要：市場概要：定義、分類、産業の現状など、市場に関する詳細なイントロダクション。
市場促進要因：市場成長に影響を与える主要促進要因・抑制要因・市場促進要因・課題を詳細に分析します。このセクションでは、技術の進歩、規制の変更、新たな動向などの要因を検証します。
セグメンテーション分析：製品タイプ、用途、エンドユーザー、地域などの基準に基づき、市場を明確なセグメントに内訳。この分析により、各セグメントの業績と将来性を明らかにします。
競合情勢：市場シェア、製品ポートフォリオ、戦略的イニシアティブ、財務実績など、主要市場参入企業の包括的評価。主要企業が採用する競合力学と主要戦略に関する考察を記載しています。
市場予測：過去のデータと現在の市場状況に基づき、一定期間における市場規模と成長動向を予測。これには、定量的分析と将来の市場軌跡を示すグラフ表示が含まれます。
地域分析：地域による市場パフォーマンスを評価し、主要市場や地域動向を明らかにします。地域の市場力学とビジネス機会を理解するのに役立ちます。
新たな動向と機会：現在の市場動向と新たな市場動向、技術革新、潜在的な投資対象セグメントを特定します。将来の市場開拓と成長展望に関する洞察を記載しています。
目次
第1章 序文
第2章 エグゼクティブサマリー
- 市場のハイライト
- 世界市場スナップショット
第3章 アトピー性皮膚炎治療の産業分析
- イントロダクション：市場力学
- 市場促進要因
- 市場抑制要因
- 市場機会
- 産業動向
- ポーターのファイブフォース分析
- 市場の魅力分析
第4章 バリューチェーン分析
- バリューチェーン分析
- 原料分析
- 原料リスト
- 原料メーカー一覧
- 主要原料の価格動向
- 潜在的バイヤーリスト
- マーケティングチャネル
- 直接マーケティング
- 間接マーケティング
- マーケティングチャネル発展動向
第5章 アトピー性皮膚炎治療の世界市場分析：薬剤タイプ別
- 薬剤タイプ別概要
- 薬剤タイプ別過去・予測データ分析
- BCR-ABLアトピー性皮膚炎治療
- 副腎皮質ステロイド薬
- カルシニューリン阻害剤
- PDE4阻害剤
- 生物製剤
- その他
第6章 アトピー性皮膚炎治療の世界市場分析：用途別
- 用途別概要
- 用途別過去・予測データ分析
- 外用薬
- 非経口剤
- 経口剤
第7章 アトピー性皮膚炎治療の世界市場分析：流通チャネル別
- 流通チャネル別概要
- 流通チャネル別過去・予測データ分析
- 病院薬局
- 小売薬局
- オンライン薬局
第8章 アトピー性皮膚炎治療の世界市場分析：地域別
- 地域別展望
- イントロダクション
- 北米売上分析
- 概要、実績と予測
- 北米：セグメント別
- 北米：国別
- 米国
- カナダ
- メキシコ
- 欧州売上分析
- 概要、実績と予測
- 欧州：セグメント別
- 欧州：国別
- 英国
- フランス
- ドイツ
- イタリア
- ロシア
- その他の欧州
- アジア太平洋売上分析
- 概要、実績と予測
- アジア太平洋：セグメント別
- アジア太平洋：国別
- 中国
- インド
- 日本
- 韓国
- オーストラリア
- 東南アジア
- その他のアジア太平洋
- ラテンアメリカ売上分析
- 概要、実績と予測
- ラテンアメリカ：セグメント別
- ラテンアメリカ：国別
- ブラジル
- アルゼンチン
- ペルー
- チリ
- その他のラテンアメリカ
- 中東・アフリカ売上分析
- 概要、実績と予測
- 中東・アフリカ：セグメント別
- 中東・アフリカ：国別一覧
- サウジアラビア
- アラブ首長国連邦
- イスラエル
- 南アフリカ
- その他の中東・アフリカ
第9章 アトピー性皮膚炎治療企業の競合情勢
- アトピー性皮膚炎治療の市場競争
- 提携・協力・契約
- 合併・買収
- 新製品の上市
- その他の開発
第10章 企業プロファイル
- 上位企業の市場シェア分析
- 市場集中度
- Pfizer Inc.
- Sanofi
- AbbVie Inc.
- Galderma Laboratories
- L.P.
- Eli Lilly And Company（Dermira）
- Regeneron Pharmaceuticals Inc.
- LEO Pharma Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Novartis AG
- Incyte Corporation
LIST OF TABLES
- Market Snapshot
- Drivers: Impact Analysis
- Restraints: Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- Analysis By Drug Type (USD MN)
- BCR-ABL Atopic Dermatitis Drugs Market Sales By Geography (USD MN)
- Corticosteroids Market Sales By Geography (USD MN)
- Calcineurin Inhibitors Market Sales By Geography (USD MN)
- PDE4 Inhibitors Market Sales By Geography (USD MN)
- Biologics Market Sales By Geography (USD MN)
- Others Market Sales By Geography (USD MN)
- Analysis By Application (USD MN)
- Topical Market Sales By Geography (USD MN)
- Parenteral Market Sales By Geography (USD MN)
- Oral Market Sales By Geography (USD MN)
- Analysis By Distribution Channel (USD MN)
- Hospital Pharmacies Market Sales By Geography (USD MN)
- Retail Pharmacies Market Sales By Geography (USD MN)
- Online Pharmacies Market Sales By Geography (USD MN)
- Global Atopic Dermatitis Drugs Market Sales By Geography (USD MN)
- North America Market Analysis (USD MN)
- United States Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate By Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- South East Asia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Atopic Dermatitis Drugs Report
- Market Research Process
- Market Research Methodology
- Global Atopic Dermatitis Drugs Market Size, By Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis By Drug Type
- Market Attractiveness Analysis By Application
- Market Attractiveness Analysis By Distribution Channel
- Market Attractiveness Analysis By Region
- Value Chain Analysis
- Global Market Analysis By Drug Type (USD MN)
- BCR-ABL Atopic Dermatitis Drugs Market Sales By Geography (USD MN)
- Corticosteroids Market Sales By Geography (USD MN)
- Calcineurin Inhibitors Market Sales By Geography (USD MN)
- PDE4 Inhibitors Market Sales By Geography (USD MN)
- Biologics Market Sales By Geography (USD MN)
- Others Market Sales By Geography (USD MN)
- Global Market Analysis By Application (USD MN)
- Topical Market Sales By Geography (USD MN)
- Parenteral Market Sales By Geography (USD MN)
- Oral Market Sales By Geography (USD MN)
- Global Market Analysis By Distribution Channel (USD MN)
- Hospital Pharmacies Market Sales By Geography (USD MN)
- Retail Pharmacies Market Sales By Geography (USD MN)
- Online Pharmacies Market Sales By Geography (USD MN)
- Global Market Sales (USD MN)
- North America Market Sales (USD MN)
- Europe Market Sales (USD MN)
- Asia Pacific Market Sales (USD MN)
- Latin America Market Sales (USD MN)
- Middle East & Africa Market Sales (USD MN)
- Recent Development in Industry
- Top Company Market Share Analysis
Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
Global Atopic Dermatitis Drugs Market size is anticipated to grow from USD 8.19 Billion in 2024 to USD 15.13 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 7.06% during the forecast period of 2026 to 2033.
The Atopic Dermatitis Drugs Market is poised for significant growth as the prevalence of atopic dermatitis, a chronic inflammatory skin condition, continues to rise. Atopic dermatitis is characterized by dry, itchy, and inflamed skin, significantly impacting patients' quality of life. The increasing awareness of the condition and its management is driving the demand for effective therapeutic options. As healthcare providers seek to improve patient outcomes and reduce the burden of symptoms, the market for atopic dermatitis drugs is expected to flourish.
Technological advancements are playing a crucial role in shaping the future of the atopic dermatitis drugs market. Innovations in topical treatments, including corticosteroids and non-steroidal anti-inflammatory drugs, are enhancing the management of flare-ups and long-term control. Additionally, the development of biologic therapies targeting specific pathways involved in inflammation is gaining traction. As pharmaceutical companies continue to invest in research and clinical trials, the market is likely to see increased adoption of novel therapies that offer improved efficacy and safety profiles.
Moreover, the growing emphasis on personalized medicine and patient-centered care is influencing the atopic dermatitis drugs market's growth trajectory. As patients become more engaged in their treatment plans, there is a rising demand for therapies that cater to individual needs and preferences. This trend is driving collaboration between healthcare providers, researchers, and patients to develop tailored treatment strategies that enhance adherence and satisfaction. As the market continues to evolve, the integration of technology, personalized approaches, and patient education will be key drivers of success.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
SEGMENTATION COVERED IN THE REPORT
By Drug Type
- BCR-ABL Atopic Dermatitis Drugs
- Corticosteroids
- Calcineurin Inhibitors
- PDE4 Inhibitors
- Biologics
- Others
By Application
- Topical
- Parenteral
- Oral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- COMPANIES PROFILED
- Pfizer Inc.
- Sanofi
- AbbVie Inc.
- Galderma Laboratories
- L.P.
- Eli Lilly and Company (Dermira)
- Regeneron Pharmaceuticals Inc.
- LEO Pharma Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Novartis AG
- Incyte Corporation
- The above list can be customized.
TABLE OF CONTENTS
1. PREFACE
- 1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology
2. EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3. ATOPIC DERMATITIS DRUGS a€" INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porters Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend
5. GLOBAL ATOPIC DERMATITIS DRUGS MARKET ANALYSIS BY DRUG TYPE
- 5.1. Overview By Drug Type
- 5.2. Historical and Forecast Data Analysis By Drug Type
- 5.3. BCR-ABL Atopic Dermatitis Drugs Historic and Forecast Sales By Regions
- 5.4. Corticosteroids Historic and Forecast Sales By Regions
- 5.5. Calcineurin Inhibitors Historic and Forecast Sales By Regions
- 5.6. PDE4 Inhibitors Historic and Forecast Sales By Regions
- 5.7. Biologics Historic and Forecast Sales By Regions
- 5.8. Others Historic and Forecast Sales By Regions
6. GLOBAL ATOPIC DERMATITIS DRUGS MARKET ANALYSIS BY APPLICATION
- 6.1. Overview By Application
- 6.2. Historical and Forecast Data Analysis By Application
- 6.3. Topical Historic and Forecast Sales By Regions
- 6.4. Parenteral Historic and Forecast Sales By Regions
- 6.5. Oral Historic and Forecast Sales By Regions
7. GLOBAL ATOPIC DERMATITIS DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL
- 7.1. Overview By Distribution Channel
- 7.2. Historical and Forecast Data Analysis By Distribution Channel
- 7.3. Hospital Pharmacies Historic and Forecast Sales By Regions
- 7.4. Retail Pharmacies Historic and Forecast Sales By Regions
- 7.5. Online Pharmacies Historic and Forecast Sales By Regions
8. GLOBAL ATOPIC DERMATITIS DRUGS MARKET ANALYSIS BY GEOGRAPHY
- 8.1. Regional Outlook
- 8.2. Introduction
- 8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
- 8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
- 8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
- 8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
- 8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis
9. COMPETITIVE LANDSCAPE OF THE ATOPIC DERMATITIS DRUGS COMPANIES
- 9.1. Atopic Dermatitis Drugs Market Competition
- 9.2. Partnership/Collaboration/Agreement
- 9.3. Merger And Acquisitions
- 9.4. New Product Launch
- 9.5. Other Developments
10. COMPANY PROFILES OF ATOPIC DERMATITIS DRUGS INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Market Concentration Rate
- 10.3. Pfizer Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
- 10.4. Sanofi
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
- 10.5. AbbVie Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
- 10.6. Galderma Laboratories
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
- 10.7. L.P.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
- 10.8. Eli Lilly And Company (Dermira)
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
- 10.9. Regeneron Pharmaceuticals Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
- 10.10. LEO Pharma Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
- 10.11. Otsuka Pharmaceutical Co. Ltd.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
- 10.12. Novartis AG
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
- 10.13. Incyte Corporation
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
